312 related articles for article (PubMed ID: 10865917)
1. Activity of terbinafine against serious fungal pathogens.
Ryder NS
Mycoses; 1999; 42 Suppl 2():115-9. PubMed ID: 10865917
[TBL] [Abstract][Full Text] [Related]
2. Activity of terbinafine against serious fungal pathogens.
Ryder NS
Mycoses; 1999 Dec; 42 Suppl 2():115-119. PubMed ID: 29265602
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi.
Garcia-Effron G; Gomez-Lopez A; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2004 Jun; 53(6):1086-9. PubMed ID: 15102749
[TBL] [Abstract][Full Text] [Related]
4. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J
Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility testing of terbinafine alone and in combination with amphotericin B, itraconazole, or voriconazole against conidia and hyphae of dematiaceous molds.
Biancalana FS; Lyra L; Moretti ML; Schreiber AZ
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):378-85. PubMed ID: 21945391
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the in vitro activity of terbinafine.
Jessup CJ; Ryder NS; Ghannoum MA
Med Mycol; 2000 Apr; 38(2):155-9. PubMed ID: 10817232
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
10. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species.
Burkhart CG; Burkhart CN; Isham N
Br J Dermatol; 2006 Feb; 154(2):341-4. PubMed ID: 16433807
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
Gupta AK; Kohli Y
Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.
Ryder NS; Wagner S; Leitner I
Antimicrob Agents Chemother; 1998 May; 42(5):1057-61. PubMed ID: 9593126
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
[TBL] [Abstract][Full Text] [Related]
16. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.
Cornely OA
Infection; 2008 Aug; 36(4):296-313. PubMed ID: 18642109
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis.
Karaarslan A; Arikan S; Ozcan M; Ozcan KM
Mycoses; 2004 Aug; 47(7):284-7. PubMed ID: 15310330
[TBL] [Abstract][Full Text] [Related]
18. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
19. [The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro].
Xu Y; Pang GR; Lü XF; Chen ZJ; Sun ST; Song JZ
Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):309-12. PubMed ID: 16762206
[TBL] [Abstract][Full Text] [Related]
20. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei.
Cao C; Liu W; Li R; Wan Z; Qiao J
J Antimicrob Chemother; 2009 Feb; 63(2):340-2. PubMed ID: 19054803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
